VSTM Verastem Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VSTM

Price (delayed)

$10.9

Market cap

$275.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.96

Enterprise value

$239.13M

Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. The company's pipeline is focused on ...

Highlights
Verastem's EPS has increased by 13% YoY and by 2.2% QoQ
Verastem's equity has decreased by 31% QoQ but it has increased by 21% YoY
Verastem's quick ratio has increased by 28% YoY but it has decreased by 25% from the previous quarter
VSTM's revenue has dropped by 100% year-on-year
VSTM's gross profit has dropped by 100% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.verastem.com
Peers: PFE CRIS LH

Key stats

What are the main financial stats of VSTM
Market
Shares outstanding
25.3M
Market cap
$275.72M
Enterprise value
$239.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.8
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$83.23M
EBITDA
-$83.34M
Free cash flow
-$86.46M
Per share
EPS
-$3.96
Free cash flow per share
-$3.92
Book value per share
$2.27
Revenue per share
$0
TBVPS
$6.79
Balance sheet
Total assets
$149.72M
Total liabilities
$71.19M
Debt
$41.56M
Equity
$57.37M
Working capital
$117.3M
Liquidity
Debt to equity
0.72
Current ratio
5.45
Quick ratio
5.21
Net debt/EBITDA
0.44
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-54.7%
Return on equity
-127%
Return on invested capital
-128%
Return on capital employed
-67.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VSTM stock price

How has the Verastem stock price performed over time
Intraday
5.21%
1 week
16.2%
1 month
-9.02%
1 year
-82.8%
YTD
33.91%
QTD
-7.63%

Financial performance

How have Verastem's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$92.08M
Net income
-$87.37M
Gross margin
N/A
Net margin
N/A
VSTM's revenue has dropped by 100% year-on-year
VSTM's gross profit has dropped by 100% year-on-year
The company's operating income fell by 26% YoY and by 18% QoQ
VSTM's net income is down by 18% year-on-year and by 14% since the previous quarter

Growth

What is Verastem's growth rate over time

Valuation

What is Verastem stock price valuation
P/E
N/A
P/B
4.8
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Verastem's EPS has increased by 13% YoY and by 2.2% QoQ
The stock's P/B is 92% above its last 4 quarters average of 2.5 and 23% above its 5-year quarterly average of 3.9
Verastem's equity has decreased by 31% QoQ but it has increased by 21% YoY
VSTM's revenue has dropped by 100% year-on-year

Efficiency

How efficient is Verastem business performance
The ROA has grown by 22% YoY but it has contracted by 4% from the previous quarter
The ROIC has grown by 17% YoY and by 13% from the previous quarter
Verastem's return on equity has decreased by 10% QoQ

Dividends

What is VSTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VSTM.

Financial health

How did Verastem financials performed over time
The total assets is 110% greater than the total liabilities
The total assets has surged by 58% year-on-year but it has declined by 15% since the previous quarter
Verastem's total liabilities has increased by 49% YoY
Verastem's debt is 28% less than its equity
Verastem's debt has soared by 54% YoY
VSTM's debt to equity is up by 41% since the previous quarter and by 26% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.